Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 2013. The report details a specific corporate action regarding share repurchases authorized by shareholders at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on share capital movements.
- Shares Purchased: 773,000 Ordinary Shares on June 11, 2013.
- Price Range: Highest price paid was 1,666.5 pence per share; lowest was 1,655.0 pence per share.
- Treasury Holdings (Settled): 508,139,512 shares (9.36% of total issued share capital).
- Treasury Holdings (Including Unsettled): 509,817,512 shares (10.36% of total voting rights).
- Shares in Issue (Excluding Treasury): 4,921,329,659 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 773,000 shares for Treasury. This action increased the percentage of total voting rights held in Treasury from the prior settled position to 10.36% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Points
- Verify the total number of shares in issue (4,921,329,659) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the current percentage of voting rights held in Treasury (10.36% including unsettled shares).
- Note that the repurchase price range (1,655.0 to 1,666.5 pence) reflects market conditions on June 11, 2013.